JDRF-funded researcher Professor Mark Cooper, Chief Scientific Officer and Head of the Diabetes Division at Baker IDI Heart and Diabetes Research Institute, has become the first Australian to receive the prestigious Claude Bernard award from the European Association for the Study of Diabetes this month.
The award recognises an individual’s innovative leadership and outstanding contributions to the expansion of knowledge in the field of diabetes and related metabolic diseases. Professor Cooper was chosen from a pool of global nominees, highlighting his international reputation and expertise.
Professor Cooper has completed much of his work on reducing the risk of diabetic complications, and has made numerous important discoveries in the field of diabetes. His early work played a key role in defining the protective effects of drugs which interrupt the renin-angiotensin system, a hormone system involved in the regulation of blood pressure.
He has a long track record of awards, and was the first ever Australian recipient of the JDRF $1.25 million Scholar Award in 2008, where he investigated a novel target for diabetic vascular complications. He currently leads the Joint National Health and Medical Research Council (NHMRC) and JDRF Diabetes Complications Centre of Research Excellence, and was recently awarded funding from the Type 1 Diabetes Clinical Research Network (T1DCRN) where he will be investigating a novel drug to prevent progression of kidney damage.
His work will go a long way toward improving the lives of people living with type 1 diabetes and its complications, while building Australia’s capacity as a leader in this important area.
JDRF Head of Research Development and Director, T1DCRN Dr Dorota Pawlak commented, “It is a privilege to know Mark, and this award is recognition of his global leadership in the field of diabetic complications. We thank him for his significant contributions and the benefits his research brings to people with type 1 diabetes.”
Read the full media release at the Baker IDI website.